Potential Impact of Higher-Valency Pneumococcal Conjugate Vaccines Among Adults in Different Localities in Germany

Mallory K Ellingson; Daniel M Weinberger; Mark van der Linden; Stephanie Perniciaro

doi:10.1093/infdis/jiad538

Potential Impact of Higher-Valency Pneumococcal Conjugate Vaccines Among Adults in Different Localities in Germany

J Infect Dis. 2023 Dec 6:jiad538. doi: 10.1093/infdis/jiad538. Online ahead of print.

Authors

Mallory K Ellingson¹, Daniel M Weinberger¹, Mark van der Linden², Stephanie Perniciaro^{1

2}

Affiliations

¹ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
² German National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany.

PMID: 38059558
DOI: 10.1093/infdis/jiad538

Abstract

Next-generation pneumococcal conjugate vaccines (PCVs) have been approved for use. The serotype distribution of pneumococcal isolates can vary between regions. To understand the potential impacts of new PCVs, we evaluated trends in invasive pneumococcal disease (IPD) among adults in Germany at a local level using Bayesian hierarchical logistic regression. There was little spatial variation in IPD cases caused by PCV13 serotypes, which dropped from 60% of IPD cases in 2006 to 30% in 2018. Over half of IPD cases in 2018 were attributable to serotypes covered by new PCVs (PCV15, PCV20), which suggests they could further reduce the burden of IPD.

Keywords: Streptococcus pneumoniae; IPD; invasive pneumococcal disease; pneumococcal disease in Germany; pneumococcal disease in adults.